Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck Serono
Biotech
Sonnet bags ex-Serono drug via Relief Therapeutics deal
The agreement tees Sonnet up to advance the asset in chemotherapy-induced peripheral neuropathy using an equity facility worth up to $100 million.
Nick Paul Taylor
Aug 12, 2019 8:13am
Lundbeck to buy Prexton for phase 2 Parkinson’s drug
Mar 16, 2018 6:52am
Merck KGaA taps CRUK, ICR for source of cancer candidates
Jan 16, 2018 7:01pm
Merck KGaA steps up Hippo pathway cancer pact with CRT
Jun 29, 2017 6:21am
Merck KGaA, Ablynx push osteoarthritis asset toward clinic
May 22, 2017 7:58am
Poxel shares jump 40% after diabetes trial hits primary goal
May 4, 2017 4:07am
